Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free HSAQ Stock Alerts

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

Health Sciences Acquisitions Co. 2 logo
$6.08 +0.30 (+5.19%)
As of 09/18/2026
Compare

HSAQ vs. ELMD, PDEX, STIM, PROF, and ZJYL

Should you buy Health Sciences Acquisitions Co. 2 stock or one of its competitors? Health Sciences Acquisitions Co. 2's main competitors and comparable companies include Electromed (ELMD), Pro-Dex (PDEX), Neuronetics (STIM), Profound Medical (PROF), and Jin Medical International (ZJYL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Health Sciences Acquisitions Co. 2 compare to Electromed?

Electromed (NYSE:ELMD) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Electromed has a net margin of 11.34% compared to Health Sciences Acquisitions Co. 2's net margin of 0.00%. Electromed's return on equity of 15.71% beat Health Sciences Acquisitions Co. 2's return on equity.

Company Net Margins Return on Equity Return on Assets
Electromed11.34% 15.71% 13.37%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

40.8% of Electromed shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 10.5% of Electromed shares are owned by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Electromed has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Electromed currently has a consensus target price of $43.75, suggesting a potential upside of 62.04%. Given Electromed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Electromed is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Electromed
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Electromed has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Electromed$73.78M3.06$5.15M$1.3120.61
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

In the previous week, Electromed had 1 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 1 mentions for Electromed and 0 mentions for Health Sciences Acquisitions Co. 2. Electromed's average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company Overall Sentiment
Electromed Neutral
Health Sciences Acquisitions Co. 2 Neutral

Summary

Electromed beats Health Sciences Acquisitions Co. 2 on 10 of the 12 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 45.9% of Pro-Dex shares are held by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Pro-Dex had 19 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 19 mentions for Pro-Dex and 0 mentions for Health Sciences Acquisitions Co. 2. Pro-Dex's average media sentiment score of 1.06 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the media.

Company Overall Sentiment
Pro-Dex Positive
Health Sciences Acquisitions Co. 2 Neutral

Pro-Dex currently has a consensus target price of $74.00, suggesting a potential upside of 2.04%. Given Pro-Dex's stronger consensus rating and higher possible upside, equities analysts plainly believe Pro-Dex is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pro-Dex
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Pro-Dex has a net margin of 17.62% compared to Health Sciences Acquisitions Co. 2's net margin of 0.00%. Pro-Dex's return on equity of 25.13% beat Health Sciences Acquisitions Co. 2's return on equity.

Company Net Margins Return on Equity Return on Assets
Pro-Dex17.62% 25.13% 16.02%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Pro-Dex has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pro-Dex$77.55M2.99$13.66M$4.1317.56
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

Pro-Dex has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Summary

Pro-Dex beats Health Sciences Acquisitions Co. 2 on 12 of the 14 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Neuronetics had 3 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 3 mentions for Neuronetics and 0 mentions for Health Sciences Acquisitions Co. 2. Neuronetics' average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company Overall Sentiment
Neuronetics Neutral
Health Sciences Acquisitions Co. 2 Neutral

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Neuronetics' net margin of -19.62%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Neuronetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neuronetics-19.62% -125.11% -22.15%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Neuronetics presently has a consensus price target of $4.67, indicating a potential upside of 63.74%. Given Neuronetics' stronger consensus rating and higher probable upside, research analysts clearly believe Neuronetics is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuronetics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 8.4% of Neuronetics shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Neuronetics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuronetics$149.16M1.46-$39M-$0.44N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

Neuronetics has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Summary

Neuronetics and Health Sciences Acquisitions Co. 2 tied by winning 6 of the 12 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Profound Medical?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Comparatively, 1.5% of Profound Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Profound Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A
Profound Medical$19.09M11.68-$42.57M-$0.98N/A

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Profound Medical's net margin of -171.57%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Profound Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Health Sciences Acquisitions Co. 2N/A N/A -2.38%
Profound Medical -171.57%-63.03%-51.24%

Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Profound Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

In the previous week, Health Sciences Acquisitions Co. 2's average media sentiment score of 0.00 equaled Profound Medical'saverage media sentiment score.

Company Overall Sentiment
Health Sciences Acquisitions Co. 2 Neutral
Profound Medical Neutral

Profound Medical has a consensus price target of $11.50, suggesting a potential upside of 88.52%. Given Profound Medical's stronger consensus rating and higher probable upside, analysts clearly believe Profound Medical is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Profound Medical
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

Summary

Health Sciences Acquisitions Co. 2 and Profound Medical tied by winning 6 of the 12 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Jin Medical International?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Jin Medical International (NASDAQ:ZJYL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Jin Medical International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Health Sciences Acquisitions Co. 2's average media sentiment score of 0.00 beat Jin Medical International's score of -0.25 indicating that Health Sciences Acquisitions Co. 2 is being referred to more favorably in the media.

Company Overall Sentiment
Health Sciences Acquisitions Co. 2 Neutral
Jin Medical International Neutral

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Jin Medical International has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A
Jin Medical International$20.69M7.85$1.19MN/AN/A

Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Jin Medical International has a beta of 7.31, indicating that its share price is 631% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Health Sciences Acquisitions Co. 2N/A N/A -2.38%
Jin Medical International N/A N/A N/A

Summary

Jin Medical International beats Health Sciences Acquisitions Co. 2 on 5 of the 8 factors compared between the two stocks.

Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically

Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HSAQ vs. The Competition

Export
MetricHealth Sciences Acquisitions Co. 2Healthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$68.17M$5.51B$7.26B$13.23B
Dividend YieldN/A1.80%2.53%12.80%
P/E RatioN/A25.32275.5725.79
Price / SalesN/A90.83693.66102.99
Price / CashN/A33.1128.0434.72
Price / Book-9.815.8810.566.36
Net Income-$380K$151.55M$3.49B$358.17M
7 Day Performance-0.65%0.05%-0.24%0.54%
1 Month Performance9.55%-3.94%-2.79%-2.94%
1 Year Performance149.18%6.56%18.26%6.08%

Health Sciences Acquisitions Co. 2 Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HSAQ
Health Sciences Acquisitions Co. 2
N/A$6.08
+5.2%		N/A+149.2%$68.17MN/AN/A4
ELMD
Electromed
2.5327 of 5 stars		$26.15
-0.5%		$43.75
+67.3%		+7.1%$218.77M$73.78M34.87197
PDEX
Pro-Dex
3.6503 of 5 stars		$71.85
+7.4%		$74.00
+3.0%		+111.1%$214.34M$77.55M17.40206
STIM
Neuronetics
3.4748 of 5 stars		$2.76
-1.4%		$4.67
+69.1%		+4.3%$213.35M$149.16MN/A658
PROF
Profound Medical
2.5746 of 5 stars		$5.83
+2.6%		$11.50
+97.3%		+35.0%$207.51M$16.10MN/A162

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HSAQ) was last updated on 9/21/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel